Skip to main content
padlock icon - secure page this page is secure


Download Article:

The full text article is available externally.

The article you have requested is supplied via the DOAJ. View from original source.

Abstract. A new role of B-cells in pathogenesis of multiple sclerosis (MS), their relations with B-cells in
development of inflammation and probable mechanisms of advanced therapeutic intervention in order to reach B-cell depletion are subject to discussion in present article. Here we describe a clinical case of MS with a resistant clinical course, and results of anti B-cell treatment. To attain maximal clinical effect, a novel therapeutic regimen (a combination of rituximab and mitozantrone) was applied. Clinical, radiological and laboratory methods were used to substantiate the efficiency of treatment.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Ленинградская областная клиническая больница (ЛОКБ), Ленинградский областной центр рассеянного склероза, Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова 2: ФГУ «Центр сердца крови и эндокринологии им. В.А. Алмазова», Санкт-Петербург 3: Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова 4: Ленинградский областной центр рассеянного склероза, Ленинградская областная клиническая больница (ЛОКБ) 5: НМЦ по молекулярной медицине МЗиСР РФ на базе Санкт-Петербургского государственного медицинского университета им. академика. И.П. Павлова

Publication date: January 1, 2009

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more